Lynch Biologics

Executive Summary

Lynch Biologics is a regenerative medicine company specializing in advanced biotechnology for oral and dental surgery. Its flagship product, GEM 21S®, combines recombinant human platelet-derived growth factor (rhPDGF-BB) with beta-tricalcium phosphate (β-TCP) to create a synthetic bone graft that promotes rapid healing and new bone formation. Acquired by Geistlich Pharma North America in 2022, the company operates as a subsidiary, leveraging Geistlich's global infrastructure and expertise in oral regeneration. Lynch Biologics' technology is well-established in dental applications, but its potential extends to broader orthopedic and craniofacial indications. As a subsidiary of a larger private firm, Lynch Biologics benefits from stable funding and operational support, yet its strategic direction is closely tied to Geistlich's portfolio. The company's near-term growth hinges on expanding the clinical footprint of GEM 21S® through new indications, geographic market penetration, and potential partnerships. With a strong product backed by clinical evidence, Lynch Biologics is positioned for steady but incremental growth within the Geistlich umbrella.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for expanded indication of GEM 21S® in orthopedic bone defects40% success
• Q3 2026Geographic expansion into Europe and Asia via Geistlich distribution network60% success
• Q2 2026Publication of clinical data supporting use in periodontal regeneration in peer-reviewed journals75% success